OncoMatch/Clinical Trials/NCT06796907
A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors
Is NCT06796907 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for tumours, gynecological.
Treatment: GSK5733584 · Dostarlimab · Bevacizumab · Anticancer therapy 3 · Anticancer therapy 4 — Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns. Researchers are developing new treatments that combine different medicines for those who do not respond to single medicine. This study is looking at how safe and tolerable GSK5733584 is, how the body handles it, and how well it works when used with other cancer medicines. The study will include participants with advanced solid tumors who have either not responded to standard treatments or cannot tolerate them or have no available effective treatment.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: VTCN1 expression (expression by IHC required for central assessment; no threshold specified)
retrospective central assessment of B7H4 expression by immunohistochemistry (IHC)
Required: MMR proficient (proficient)
confirmed mismatch repair proficient (MMRp) ... tumor status by local test
Required: MSS stable (stable)
microsatellites stable (MSS) tumor status by local test
Disease stage
Metastatic disease required
Participants with pathologically confirmed advanced solid tumor specific for study arms
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard systemic therapy
failed in adequate standard treatments, do not have effective standard treatment or are intolerant to standard of care
Cannot have received: anti-PD-1/PD-L1 therapy
Participants naïve to anti-programmed death protein 1 and/or programmed death ligand 1 (PD[L]-1) anti-cancer therapy
Cannot have received: cytotoxic chemotherapy, endocrine therapy, molecular targeted therapy, immunotherapy, biotherapy, investigational drug
Has received treatment with any cytotoxic chemotherapy drugs or other anti-tumor drugs (including endocrine therapy, molecular targeted therapy, immunotherapy, biotherapy, and investigational drug) within 30 days or 5 half-lives, whichever is shorter of a medicinal product prior to the first dose of study drug; or need to continue these drugs during the study
Cannot have received: locoregional radiation therapy
Have received locoregional radiation therapy within 2 weeks prior to the first dose of study drug; more than 30% of bone marrow irradiation or wide-field radiation therapy within 4 weeks prior to the first dose of study treatment
Lab requirements
Blood counts
Participants with normal organ and bone marrow function
Kidney function
no active renal condition (e.g., infection, requirement for dialysis, or any other active significant renal condition or dehydrated condition)
Liver function
ALT value >2.5x ULN; for participants with documented liver metastases/tumor infiltration ALT value >5x ULN; total bilirubin value >1.5x ULN
Cardiac function
history in prior year of clinically significant or uncontrolled cardiac disease, acute myocardial infarction, or clinically significant arrhythmia not controlled by standard of care therapy; QTcF >450 msec or >480 msec for participants with bundle branch block
Participants with normal organ and bone marrow function; ALT value >2.5x ULN ... total bilirubin value >1.5x ULN; ... any active renal condition ... history in prior year of clinically significant or uncontrolled cardiac disease ... QTcF >450 msec or >480 msec for participants with bundle branch block
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify